Cytokinetics, Inc.
General ticker "CYTK" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.9B
Cytokinetics, Inc. does not follow the US Stock Market performance with the rate: -30.4%.
Estimated limits based on current volatility of 2.8%: low 46.64$, high 49.37$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [25.37$, 55.08$]
- 2024-12-30 to 2025-12-30 estimated range: [21.03$, 47.13$]
Financial Metrics affecting the CYTK estimates:
- Negative: Non-GAAP EPS, $ of -5.45 <= 0.10
- Negative: Operating profit margin, % of -98.51 <= 1.03
- Negative: Operating cash flow per share per price, % of -10.66 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Positive: Inventory ratio change, % of -0.16 <= 0
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term CYTK quotes
Long-term CYTK plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $70.43MM | $94.59MM | $7.53MM |
| Operating Expenses | $256.74MM | $418.79MM | $503.74MM |
| Operating Income | $-186.31MM | $-324.20MM | $-496.20MM |
| Non-Operating Income | $-29.33MM | $-76.09MM | $-30.04MM |
| Interest Expense | $29.33MM | $51.16MM | $57.67MM |
| R&D Expense | $159.94MM | $6.59MM | $0.00MM |
| Income(Loss) | $-215.65MM | $-400.30MM | $-526.24MM |
| Profit(Loss) | $-215.65MM | $-400.30MM | $-526.24MM |
| Stockholders Equity | $243.86MM | $-107.90MM | $-386.32MM |
| Inventory | $51.82MM | $0.15MM | $0.00MM |
| Assets | $841.32MM | $1,014.77MM | $824.32MM |
| Operating Cash Flow | $-142.52MM | $-299.52MM | $-414.33MM |
| Capital expenditure | $48.87MM | $11.34MM | $1.42MM |
| Investing Cash Flow | $-147.78MM | $-262.13MM | $239.25MM |
| Financing Cash Flow | $319.98MM | $516.17MM | $221.32MM |
| Earnings Per Share* | $-3.15 | $-4.48 | $-5.45 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.